Boothby Counseling Services, Llc | |
656 520th St Alta IA 51002-7535 | |
(712) 251-5308 | |
Not Available |
Full Name | Boothby Counseling Services, Llc |
---|---|
Speciality | Counselor - Mental Health |
Location | 656 520th St, Alta, Iowa |
Authorized Official Name and Position | Manda Boothby (MENTAL HEALTH THERAPIST) |
Authorized Official Contact | 7122515308 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Boothby Counseling Services, Llc 656 520th St Alta IA 51002-7535 Ph: (712) 251-5308 | Boothby Counseling Services, Llc 656 520th St Alta IA 51002-7535 Ph: (712) 251-5308 |
NPI Number | 1912779851 |
---|---|
Provider Enumeration Date | 10/24/2023 |
Last Update Date | 10/24/2023 |
Certification Date | 10/24/2023 |
Identifier | Type | State | Issuer |
---|---|---|---|
1912779851 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
News Archive
Lung cancer diagnosis tool shown to be safe and effective for older patientsA recent study in Manchester has found that a procedure to take tissue samples from lung cancer patients can be used safely in the elderly - allowing doctors to make a more accurate diagnosis and to choose appropriate treatment.
Point-of-Care Partners—a national health information technology strategy and management consulting firm—was recognized on September 21 for its role in helping Michigan attain the nation's second highest rate of ePrescribing in 2009. The commendation came as part of Surescripts' fifth annual Safe-Rx Awards, which are based on several factors including each state's overall ePrescribing volume.
Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.
A novel class of antimalarial compounds that can effectively kill malaria parasites has been developed by Australian and US researchers.
› Verified 9 days ago